Aripiprazole Lauroxil
Therapeutic Segment Antipsychotic
CAS No. 1259305-29-7
Regulatory Filing USDMF, E-DMF
Development Status DMF Filed
Molecule Type Small Molecule
Enquire Now
Mechanism of Action

The action of aripiprazole is mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors resulting in the management of positive, negative, and cognitive symptoms in schizophrenia.

Disclaimer: No information in this Catalog – including any reference to any product or service – constitutes an offer for sale or be constructed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, under Bolar Provision the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of patent scenario for their respective markets and will be responsible for all patent related liabilities.